Clear Harbor Asset Management LLC Acquires New Shares in Stryker Corporation $SYK

Key Points

• Clear Harbor Asset Management acquired 3,551 Stryker shares worth approximately $1.12 million in the second quarter, while institutional investors and hedge funds collectively own 77.09% of the stock.
• Stryker reported stronger-than-expected quarterly results, with earnings of $3.69 per share and revenue of $6.59 billion, up 9.4% year over year. The company maintained fiscal 2026 EPS guidance of $14.95–$15.10 and declared a quarterly dividend of $0.88 per share.
• Analysts maintain a broadly positive outlook, with a consensus “Moderate Buy” rating and an average price target of $386.28, but insider selling remains a concern: company insiders sold 665,370 shares worth $216.2 million over the past 90 days.

Clear Harbor Asset Management LLC bought a new stake in Stryker Corporation (NYSE:SYK - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,551 shares of the medical technology company's stock, valued at approximately $1,118,000.

Several other hedge funds also recently bought and sold shares of SYK. Gables Capital Management Inc. acquired a new stake in shares of Stryker during the 2nd quarter valued at about $25,000. Kilter Group LLC acquired a new position in Stryker in the second quarter worth approximately $25,000. Godfrey Financial Associates Inc. acquired a new position in Stryker in the fourth quarter worth approximately $26,000. Sankala Group LLC bought a new position in Stryker during the fourth quarter valued at approximately $26,000. Finally, Compass Financial Management LLC bought a new position in Stryker during the second quarter valued at approximately $27,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 50,000 shares of the business's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the transaction, the director owned 2,251,375 shares of the company's stock, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Debra King sold 826 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider owned 6,210 shares of the company's stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 665,370 shares of company stock worth $216,238,501 over the last ninety days. Company insiders own 4.60% of the company's stock.

Stryker Trading Up 0.7%

Shares of SYK stock opened at $329.86 on Friday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The company has a market cap of $126.52 billion, a PE ratio of 34.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The business's 50 day moving average is $326.99 and its two-hundred day moving average is $332.64.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts' consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker's revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the previous year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker's dividend payout ratio is 36.48%.

Wall Street Analyst Weigh In

Several analysts have commented on SYK shares. Raymond James Financial set a $370.00 target price on shares of Stryker in a research report on Friday, July 31st. Robert W. Baird set a $385.00 price target on shares of Stryker in a report on Friday, May 1st. Needham & Company LLC reduced their price objective on shares of Stryker from $454.00 to $418.00 and set a "buy" rating for the company in a research note on Friday, May 1st. BMO Capital Markets assumed coverage on shares of Stryker in a report on Wednesday, July 8th. They issued an "outperform" rating and a $369.00 price objective for the company. Finally, Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $386.28.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source